BACKGROUND: Because 80% of cervical cancers arise in low-resource settings, many inexpensive strategies are being tested. In that spirit, the authors are testing large-scale genomic or DNA ploidy measurements as an inexpensive and semiautomated strategy. METHODS: Patients entered either a screening or diagnostic study of several optical technologies: quantitative cytology, quantitative histopathology, and fluorescence and reflectance spectroscopy using a point probe, a multispectral digital colposcope, or a combination of the two. We calculated sensitivities, specificities, positive and negative predictive values, and their confidence interval testing conventional cytology, Hybrid Capture (HC) II testing, and DNA ploidy measured on the Feulgen-stained quantitative Pap smear. RESULTS: The current investigation reports on 1555 patients for whom colposcopically directed biopsies were read 3 times by study pathologists. The final histopathologic diagnosis was high grade (cervical intraepithelial neoplasia [CIN] 2, CIN 3, carcinoma in situ [CIS], and cancer) in 16% of patients. Using high-grade squamous intraepithelial lesions (SILs) histopathology as the threshold and gold standard, the sensitivity and specificity, respectively, were: 0.47 and 0.96 for conventional cytology, 0.91 and 0.80 for HC II, and 0.59 and 0.93 for DNA ploidy. The positive and negative predictive values (PPV, NPV) for conventional cytology were 0.70 and 0.90, 0.46 and 0.98 for HC II, and 0.63 and 0.92 for DNA ploidy. CONCLUSIONS: DNA ploidy shows comparable sensitivity, specificity, PPV, and NPV values to conventional cytology and HC II. Unlike conventional cytology, DNA ploidy is semiautomated and can be performed in less than 8 hours. Cost effectiveness studies are under way, but in the authors' laboratory DNA ploidy is inexpensive.
BACKGROUND: Because 80% of cervical cancers arise in low-resource settings, many inexpensive strategies are being tested. In that spirit, the authors are testing large-scale genomic or DNA ploidy measurements as an inexpensive and semiautomated strategy. METHODS:Patients entered either a screening or diagnostic study of several optical technologies: quantitative cytology, quantitative histopathology, and fluorescence and reflectance spectroscopy using a point probe, a multispectral digital colposcope, or a combination of the two. We calculated sensitivities, specificities, positive and negative predictive values, and their confidence interval testing conventional cytology, Hybrid Capture (HC) II testing, and DNA ploidy measured on the Feulgen-stained quantitative Pap smear. RESULTS: The current investigation reports on 1555 patients for whom colposcopically directed biopsies were read 3 times by study pathologists. The final histopathologic diagnosis was high grade (cervical intraepithelial neoplasia [CIN] 2, CIN 3, carcinoma in situ [CIS], and cancer) in 16% of patients. Using high-grade squamous intraepithelial lesions (SILs) histopathology as the threshold and gold standard, the sensitivity and specificity, respectively, were: 0.47 and 0.96 for conventional cytology, 0.91 and 0.80 for HC II, and 0.59 and 0.93 for DNA ploidy. The positive and negative predictive values (PPV, NPV) for conventional cytology were 0.70 and 0.90, 0.46 and 0.98 for HC II, and 0.63 and 0.92 for DNA ploidy. CONCLUSIONS: DNA ploidy shows comparable sensitivity, specificity, PPV, and NPV values to conventional cytology and HC II. Unlike conventional cytology, DNA ploidy is semiautomated and can be performed in less than 8 hours. Cost effectiveness studies are under way, but in the authors' laboratory DNA ploidy is inexpensive.
Authors: Timon P H Buys; Scott B Cantor; Martial Guillaud; Karen Adler-Storthz; Dennis D Cox; Clement Okolo; Oyedunni Arulogon; Oladimeji Oladepo; Karen Basen-Engquist; Eileen Shinn; José-Miguel Yamal; J Robert Beck; Michael E Scheurer; Dirk van Niekerk; Anais Malpica; Jasenka Matisic; Gregg Staerkel; Edward Neely Atkinson; Luc Bidaut; Pierre Lane; J Lou Benedet; Dianne Miller; Tom Ehlen; Roderick Price; Isaac F Adewole; Calum MacAulay; Michele Follen Journal: Gend Med Date: 2011-09-22
Authors: Scott B Cantor; Jose-Miguel Yamal; Martial Guillaud; Dennis D Cox; E Neely Atkinson; John L Benedet; Dianne Miller; Thomas Ehlen; Jasenka Matisic; Dirk van Niekerk; Monique Bertrand; Andrea Milbourne; Helen Rhodes; Anais Malpica; Gregg Staerkel; Shahla Nader-Eftekhari; Karen Adler-Storthz; Michael E Scheurer; Karen Basen-Engquist; Eileen Shinn; Loyd A West; Anne-Therese Vlastos; Xia Tao; J Robert Beck; Calum Macaulay; Michele Follen Journal: Int J Cancer Date: 2010-11-09 Impact factor: 7.396
Authors: Jose-Miguel Yamal; Martial Guillaud; E Neely Atkinson; Michele Follen; Calum MacAulay; Scott B Cantor; Dennis D Cox Journal: Stat Anal Data Min Date: 2015-04-08 Impact factor: 1.051